Sudeep Pharma IPO Subscribed 94 Times
Sudeep Pharma's ₹895 crore IPO witnessed massive demand, subscribed 94 times. QIB portion booked 213x. Shares may list at a 14% premium. Key details inside.
Category : Search result: Indian pharma growth
Sudeep Pharma IPO Subscribed 5.09x, Closes Nov 25
Sudeep Pharma IPO sees massive 5.09x subscription on Day 2. Grey market premium hits ₹86. Allotment scheduled for November 26. Apply before closing tomorrow!
Lupin: Undervalued Pharma Giant at 21x P/E?
Lupin stocks trade at 21.7x P/E despite record earnings and 80 new products pipeline. Discover why this pharma giant might be undervalued and poised for next growth cycle with biosimilars and complex generics.
Sudeep Pharma IPO Day 2: GMP Signals Strong Gains
Sudeep Pharma's ₹895 crore IPO is fully subscribed. With a GMP of ₹121, investors eye a 20% listing gain. Track all live updates here.
Sudeep Pharma IPO Fully Subscribed on Day 1
Sudeep Pharma's IPO concludes November 25 after strong第一天 response. Grey market premium hits ₹121, signaling 20% listing gains. Key dates and subscription details revealed.
Aurobindo Pharma China Facility Targets Break-Even by FY26
Aurobindo Pharma's China facility currently faces $1M loss but aims for break-even by Q3-Q4 FY26. CFO outlines growth drivers including Pen-G ramp-up and biosimilar commercialization.
Karnataka Health Minister's Directive to Pharma Industry
Karnataka Health Minister Dinesh Gundu Rao urges the pharma sector to adhere to regulations, highlighting critical public health and industry credibility issues.
Eli Lilly First Pharma to Reach $1 Trillion Market Cap
Eli Lilly makes pharmaceutical history as first company to achieve $1 trillion market capitalization after shares rose 1.7% on November 21, 2025. Learn what this means for investors.
Smallcap Pharma Stock Gains 10% Despite Market Sell-Off
A smallcap pharma stock listed on NSE defied market trends with a 10% surge on November 21, 2024. Discover the driving factors behind this remarkable performance.
IPO Market Sees ₹76,000 Crore Pipeline in Nov 2025
India's IPO market surges with ₹76,000 crore offerings. Excelsoft Technologies fully subscribed, Sudeep Pharma at 50%. Expert analysis on both IPOs and GMP trends revealed.
Sudeep Pharma IPO: ₹895 Cr Offer Opens, ₹130 Grey Market Premium
Sudeep Pharma's ₹895 crore IPO opens with ₹563-593 price band. Grey market shows ₹130 premium. Analysts recommend long-term investment for 2-5 years horizon.
Sudeep Pharma IPO: ₹895 Crore Offer Opens Today
Sudeep Pharma's ₹895 crore IPO opens today. Price band ₹563-593 per share. Learn about company details, investment minimums & global presence. Subscribe now!
Sudeep Pharma IPO: 22% GMP, Opens Nov 21
Sudeep Pharma's ₹95 crore IPO opens November 21 with strong grey market premium. Learn price band, dates, financials & investment details for this pharma ingredients maker.
Sudeep Pharma IPO: ₹895 Cr Issue Opens Nov 21
Sudeep Pharma's ₹895 crore IPO opens November 21-25. Price band ₹563-593 per share. Company manufactures pharmaceutical excipients and speciality ingredients.
Sudeep Pharma IPO: Price Band ₹563-593 Per Share
Sudeep Pharma IPO opens November 21 with price band ₹563-593 per share. Company aims to raise ₹95 crore. Learn key dates, financials, and investment details.
Remedium Lifecare Q2 Profit Jumps 92% to ₹38.62 Cr
Remedium Lifecare reports stellar Q2 results with profit nearly doubling to ₹38.62 crore. Revenue surges 22% driven by strong pharmaceutical exports and domestic growth.
European Pharma Stocks Rebound from AI Shift
European weight-loss drug makers surge as investors rotate capital from expensive AI stocks into healthcare. Zealand Pharma leads with a 20% weekly jump. Explore the market dynamics.
Purdue Pharma Wins Bankruptcy Approval in Opioid Case
Purdue Pharma receives court approval for $7.4 billion opioid settlement after Supreme Court intervention. Sackler family to pay $6.5 billion over 15 years in landmark case.
Purdue Pharma $7B Opioid Settlement Gets Court Nod
Federal judge approves Purdue Pharma's bankruptcy plan requiring Sackler family to pay $7 billion and surrender company ownership. Thousands of opioid victims to receive compensation in historic settlement.
Lincoln Pharma Aims for Rs 1000 Crore Revenue
Lincoln Pharmaceuticals Ltd announces ambitious plan to achieve Rs 1000 crore revenue within three years through strategic expansion and new product launches. Read more about their growth strategy.
OneSource Pharma Raises FY28 Revenue Target to $500M
OneSource Pharma hikes FY28 revenue guidance to over $500 million, plans $100M expansion for weight-loss drugs like semaglutide. CEO reveals accelerated growth strategy.
Gujarat Pharma Factory Blast: 2 Dead, 20 Injured
Tragic boiler explosion at pharmaceutical factory in Gujarat's Bharuch district claims 2 lives, leaves 20 injured. Massive fire brought under control by emergency teams.
India's Drug Regulator Tightens Pharma Quality Control
India's DCGI orders nationwide inspections of small pharma units as WHO flags toxic cough syrups. MSMEs struggle to meet new Schedule M compliance deadline of January 2026.
Indian Pharma Units Face Closure Over GMP Non-Compliance
DCGI directs state authorities to enforce strict GMP compliance by December 31, 2025. Delhi, Himachal Pradesh, Uttarakhand already taking action against non-compliant manufacturers.
DCGI Orders Global Pharma Standards Implementation by Jan 2026
India's drug regulator DCGI mandates global manufacturing standards for all pharma companies by January 2026. State regulators ordered to begin inspections immediately. Read about the strict compliance requirements.
Sun Pharma: US Tariff Clarity & Q2 FY26 Outlook
Sun Pharma investors await Q2 FY26 results with cautious optimism as US tariff clarity emerges. Discover how import duties and market dynamics could impact India's pharmaceutical giant.
Indian Pharma Soars with Record US Generic Drug Profits
Indian pharmaceutical companies are reporting exceptional earnings driven by US generic drug sales, leading to major fundraising initiatives for expansion into medtech and wellness sectors.
AstraZeneca Q3 Profit Jumps 77% to $2.53 Billion
British-Swedish pharma giant AstraZeneca reports blockbuster Q3 results with profits surging 77% to $2.53 billion, driven by robust cancer drug sales and strategic US market expansion.
Piramal Pharma Bets on US Biopharma Funding Revival
Piramal Pharma anticipates significant growth as US biopharma funding shows recovery signs, with CDMO business poised for major expansion.
Solara Pharma Q2 Loss: ₹10 Crore Amid Challenges
Solara Active Pharma Sciences faces challenging quarter with ₹10 crore net loss despite revenue growth. Discover the operational challenges and management's recovery strategy.
Page 3 of 4